Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK3532795 is a potent, orally active, second-generation HIV-1 maturation inhibitor (EC50s: 10.2, 1.9, 2.7, and 13 nM for HIV-1 WT(human serum), HIV-1 WT, HIV-1 V370A, and HIV-1 ΔV370).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約8-10 週間 | ¥ 452,500 |
50 mg | 約8-10 週間 | ¥ 592,500 |
100 mg | 約8-10 週間 | ¥ 780,500 |
ターゲット&IC50 | HIV-1 (V370): 13 nM , HIV-1 (V370A): 2.7 nM , HIV-1 (WT): 10.2 nM , HIV-1 (WT):(EC50)1.9 nM |
In vitro | GSK3532795 demonstrates binding affinities, expressed as equilibrium dissociation constants (Kds), of 3.2 ± 0.6 nM for HIV wild-type (WT), 4.3 ± 2.0 nM for the HIV V362I variant, 6.5 ± 2.2 nM for the HIV V370A variant, and 33.6 ± 5.9 nM for the HIV ΔV370 variant, indicating its effectiveness in targeting different forms of HIV. |
別名 | BMS-955176 |
分子量 | 691.02 |
分子式 | C42H62N2O4S |
CAS No. | 1392312-45-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK3532795 1392312-45-6 Others BMS955176 BMS 955176 GSK 3532795 GSK-3532795 BMS-955176 Inhibitor inhibitor inhibit